Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc > Comparison with STR-002
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Breakthoroughon Dec 04, 2020 12:44pm
222 Views
Post# 32037782

RE:RE:RE:Comparison with STR-002

RE:RE:RE:Comparison with STR-002Thanks, qwerty22. I guess you wanted to say 1 (not 10) ongoing below six months. Anyway, the maximum of patients that can reach 12 months in this trial is 11 out of 31 (36% aprox). There will most probably be less than that, of course.The number of patients with "clinical benefit" at 12 months in the DPX trial is 26%.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities